Nyxoah and Vanderbilt University enter exclusive licensing agreement - Gilde Healthcare

Nyxoah and Vanderbilt University enter exclusive licensing agreement

2. Februar 2021

Utrecht (The Netherlands) – Nyxoah SA (Euronext: NYXH) (“Nyxoah” or the “Company”), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the Company has signed an exclusive license agreement with Vandebilt University, Nashville – TN, USA.

The agreement allows Nyxoah to further develop new neurostimulation technologies for the treatment of sleep disordered breathing conditions that were invented by Dr. David T. Kent. New treatments will focus, among others, on stimulating the ansa cervicalis, the efferent fiber of the glossopharyngeal nerve or nerves that innervate the palatoglossus and/or the palatopharyngeus muscle. Nyxoah will also work together with Vanderbilt University to continue prosecution of patent applications, which will give Nyxoah the exclusive right to use these new technologies once patents will be granted.

Under this agreement, Nyxoah shall develop a next generation neurostimulation-based solution to treat Obstructive Sleep Apnea patients. Obstructive Sleep Apnea is the most common sleep disordered breathing condition, affecting almost 1 billion people globally1. Over the past decade, neurostimulation therapies, such as the proprietary Genio® system developed and commercialized by Nyxoah, have proven their long-term efficacy in efficiently treating OSA patients.

Olivier Taelman, Chief Executive Officer of Nyxoah, commented: “We are delighted to start collaborating with Vanderbilt University, a worldwide recognized US university in this field of research, through this exclusive licensing agreement. This will open new horizons in the field of neurostimulation technologies, improving and expanding current treatment solutions for OSA patients, and will reinforce Nyxoah’s future pipeline. The upcoming collaboration with Dr. Kent at Vanderbilt University Medical Center, together with Nyxoah’s groundbreaking approach in neurostimulation and its collaboration with international key opinions leaders, will help Nyxoah strengthen its position as innovator offering patient-centered solutions.”

For further information, please contact:

Nyxoah
Milena Venkova, Corporate Communications Manager
milena.venkova@nyxoah.com
+32 490 11 93 57

About Nyxoah

Nyxoah is a healthtech company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a CE-validated, patient-centered, next generation hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk2 and comorbidities including cardiovascular diseases, depression and stroke.

Following the successful completion of the BLAST OSA study in patients with moderate to severe OSA, the Genio® system received its European CE Mark in 2019. The Company is currently conducting the BETTER SLEEP study in Australia and New Zealand for therapy indication expansion, the DREAM IDE pivotal study for FDA approval and a post-marketing EliSA study in Europe to confirm the long-term safety and efficacy of the Genio® system. For more information, please visit www.nyxoah.com.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, medtech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com.

Gilde Healthcare company Nalu appoints Thomas West as new president and CEO

Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer....
19. Juli 2022

Gilde Healthcare bolsters its Private Equity team in Frankfurt office

Dutch sector specialist Gilde Healthcare announces two new hires to its private equity team in Germany, following the recent close of its new €518m lower mid-market fund Gilde Healthcare Private Equity IV. With the recruitment...
12. Juli 2022

Gilde Healthcare company Zetacom acquires communication specialist Ooperon

Dutch communication system integrator Zetacom B.V. announced the acquisition of communication specialist Ooperon B.V.. Ooperon provides specialist solutions for critical communication in healthcare and personal security. The add-on of Ooperon marks Zetacom's third acquisition since...
11. Juli 2022